Загрузка...
Ibrutinib treatment improves T cell number and function in CLL patients
BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton’s tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies. METHODS. Peripheral...
Сохранить в:
| Опубликовано в: : | J Clin Invest |
|---|---|
| Главные авторы: | , , , , , , , , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society for Clinical Investigation
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5531425/ https://ncbi.nlm.nih.gov/pubmed/28714866 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI89756 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|